Drugs
Donidalorsen: First Approval.
Yahiya Y Syed
Published: 202510.1007/s40265-025-02257-y
Abstract
Donidalorsen (DAWNZERA™) is a first-in-class, RNA-targeted antisense oligonucleotide (ASO), developed by Ionis Pharmaceuticals for the prevention of hereditary angioedema (HAE) attacks. It received its first approval on 21 August 2025 in the USA for…
Preview only. Read the full abstract at the source